Bioelectronics Corp (BIEL)

[JNdouble1]

IR confirmed that, "The KT agreement has been modified to no longer grant it exclusivity in North America".

I can't help but see this as a negative development. KT now has no real incentive to try harder. My guess is they will sell through whatever inventory they have and walk away. BIEL is now undercutting DonJoy's price as well.

It feels like Kelly has decided to focus solely on the RecoveryRx product. Since we don't have an established market ready for the product, the next few quarters could be rough. You said, "If one’s focus is on sales for a quarter or two or more, that’s not seeing the forest for the trees", but it's not that mine or others focus is on the next quarter or two, it's that our focus has been on the next quarter or two for several years now. It's not the forest or the trees that are causing concern, it's the lack of a clear path out of the darkness.

So, this stock defaults back to being an upcoming catalyst play, a swing trade, or a flip however you want to look at it. Long term there are just so many better ways to put investment money to work. Next up, a meeting with folks at Walter Reed. The CEO put it out there herself, but then she walked it back a bit saying "a meeting with Walter Reed is just that-a meeting. It’s hardly material news". So that is probably not much to look forward to. Looks like the next real catalyst will be the clinical trials coming out of San Diego.

btw, is KT losing exclusivity material news?